Scancell Holdings Plc Block Listing Six Monthly Return (2945Q)

TIDMSCLP

RNS Number : 2945Q

Scancell Holdings Plc

17 October 2023

Scancell Holdings plc

("Scancell" or the "Company")

Block Listing Six Monthly Return

Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer and infectious disease, today makes the following notification pursuant to Schedule Six of the AIM Rules for Companies regarding its existing block admission arrangements:

 
 Name of applicant:                           Scancell Holdings plc 
 Number and class of securities               2,880,000 ordinary shares of 
  originally admitted:                         GBP0.001 each 
                                             -------------------------------------- 
 Date of admission:                           17 April 2023 
                                             -------------------------------------- 
 Period of return:                From:       17 April 2023   To:   16 October 2023 
                                 ----------  --------------  ----  ---------------- 
 Balance of unallotted securities 
  under scheme(s) from previous 
  return:                                     0 
                                             -------------------------------------- 
 Plus: The amount by which the 
  block scheme(s) has been increased 
  since the date of the last 
  return (if any increase has 
  been applied for):                          0 
                                             -------------------------------------- 
 Less: Number of securities 
  issued/allotted under scheme(s) 
  during period (see LR3.5.7G):               1,260,000 
                                             -------------------------------------- 
 Equals: Balance under scheme(s) 
  not yet issued/allotted at 
  end of period:                              1,620,000 
                                             -------------------------------------- 
 Total number of securities 
  in issue at the end of the 
  period                                      819,663,561 
                                             -------------------------------------- 
 
 
 
 
 For further information, please contact: 
 Scancell Holdings plc                                                                   +44 (0) 20 3709 5700 
 Dr Jean-Michel Cosséry, Non-Executive Chairman 
 Professor Lindy Durrant, CEO 
 Stifel Nicolaus Europe Limited (Nominated Adviser and Joint Broker)                     +44 (0) 20 7710 7600 
 Nicholas Moore/Samira Essebiyea/William Palmer-Brown (Healthcare Investment Banking) 
 Nick Adams/Nick Harland (Corporate Broking) 
 
 Panmure Gordon (UK) Limited (Joint Broker)                                              +44 (0) 20 7886 2500 
 Freddy Crossley/Emma Earl (Corporate Finance) 
 Rupert Dearden (Corporate Broking) 
 
 ICR Consilium                                                                           Tel.: +44 (0) 20 3709 5700 
 Mary-Jane Elliott/Matthew Neal/Chris Welsh                                              scancell@consilium-comms.com

About Scancell

Scancell is a clinical stage biopharmaceutical company that is leveraging its proprietary research, built up over many years of studying the human adaptive immune system, to generate novel medicines to treat significant unmet needs in cancer and infectious disease. The Company is building a pipeline of innovative products by utilising its four technology platforms: Moditope (R) and ImmunoBody (R) for vaccines and GlyMab(R) and AvidiMab (R) for antibodies.

Adaptive immune responses include antibodies and T cells (CD4 and CD8), both of which can recognise damaged or infected cells. In order to destroy such cancerous or infected cells, Scancell uses either vaccines to induce immune responses or monoclonal antibodies (mAbs) to redirect immune cells or drugs. The Company's unique approach is that its innovative products target modifications of proteins and lipids. For the vaccines (Moditope (R) and ImmunoBody (R) ) this includes citrullination and homocitrullination of proteins, whereas its mAb portfolio targets glycans or sugars that are added onto proteins and / or lipids (GlyMab(R) ) or enhances the potency of antibodies and their ability to directly kill tumour cells (AvidiMab (R) ).

For further information about Scancell, please visit: https://www.scancell.co.uk/

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

BLRBRBDGXDBDGXL

(END) Dow Jones Newswires

October 17, 2023 02:00 ET (06:00 GMT)

Scancell (AQSE:SCLP.GB)
過去株価チャート
から 12 2024 まで 1 2025